References
- IMS Health. The global use of medicines: Outlook through 2016. 2012. Available from: http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS Institute for Healthcare Informatics/Global Use of Meds 2011/Medicines_Outlook_Through_2016_Report.pdf [cited 10 October 2013]..
- Datamonitor. Branded prescription pharmaceutical sales outlook to 2016. 2012; Report Ref: HC00229-001. Available from: https://service.datamonitorhealthcare.com/ [cited 10 October 2013]..
- Eurostat. Population structure and ageing. 2012. Available from: http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Population_structure_and_ageing [cited 10 October 2013]..
- European Directive 2010/84/EU of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf [cited 10 October 2013]..
- Health Policy Advisory Committee on Technology (HealthPACT) website. Available from: http://www.health.qld.gov.au/healthpact/default.asp [cited 10 October 2013]..
- NIHR Horizon Scanning Centre website. Available from: http://www.hsc.nihr.ac.uk/about-us/ [cited 10 October 2013]..
- European Medicines Agency. Central authorization of medicines. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000109.jsp [cited 10 October 2013]..
- European Commission. The 2012 ageing report-economic and budgetary projection for the 27 EU Member States (2010–2060). 2012; European Economy 2. Available from: http://ec.europa.eu/economy_finance/publications/european_economy/2012/pdf/ee-2012-2_en.pdf [cited 10 October 2013]..
- Vataire A-L , Cetinsoy L , Aballéa S , Rémuzat C , Urbinati D , Kornfeld Å Novel methodology for pharmaceutical expenditure forecast. J Market Access Health Policy. 2014; 2 http://dx.doi.org/10.3402/jmahp.v2.24082 .
- Datamonitor. Biosimilars: Pipeline trends. 2011; Report Ref: HC00149-002. Available from: https://service.datamonitorhealthcare.com/ [cited 10 October 2013]..
- IMS Health. Shaping the biosimilar opportunity: A global perspective on the evolving biosimilars landscape. 2011. Available from: http://www.imshealth.fr/ims/Global/Content/Home Page Content/IMS News/Biosimilars_Whitepaper.pdf [cited 10 October 2013]..
- Generics and Biosimilars Initiative (GaBi). US$67 billion worth of biosimilar patents expiring before 2020. 2012. Available from: http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020 [cited 22 August 2012]..
- The identity problem. Editorial. Nat Biotechnol 2010;28(9): 877. Available from: http://www.nature.com/nbt/journal/v28/n9/full/nbt0910-877.html [cited 22 August 2012]..
- European Medicines Agency (EMA). Concept paper on the revision of the guideline on non- clinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins. 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109588.pdf [cited 22 August 2012]..
- Generics and Biosimilars Initiative (GaBi). Copaxone sees off generics challenge. 2012. Available from: http://www.gabionline.net/Generics/News/Copaxone-sees-off-generics-challenge [cited 22 August 2012]..